NEWS Oncoscience signs contract with YM Biosciences Inc. ByOncoscience 15. November 200317. July 2025 Read the press release Download: >> press_release_YM_Biosciences (.pdf 28kB) Ähnliche Beiträge
Allgemein | NEWS Specific Pharma A/S and Oncoscience GmbH launch a Named Patient Program for the treatment of cancer with nimotuzumab. ByOncoscience 6. November 202017. July 2025
NEWS Oncoscience AG receives EU orphan drug status for the EGFR monoclonal antibody Nimotuzumab (Theraloc®) for the treatment of pancreatic cancer. ByOncoscience 22. April 200817. July 2025
NEWS Oncoscience AG established scientific advisory board ByOncoscience 15. October 200417. July 2025
NEWS The European Medicines Agency, EMEA, concludes its formal validation of the marketing authorization application for Theraloc® (Nimotuzumab) positively ByOncoscience 26. October 200717. July 2025
NEWS YM BioSciences and Oncoscience Report Response Rate of 35.3% in Pediatric Glioma ByOncoscience 1. March 200517. July 2025
